Literature DB >> 15857116

1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.

Gary T Wang1, Gaoquan Li, Robert A Mantei, Zehan Chen, Peter Kovar, Wendy Gu, Zhan Xiao, Haiying Zhang, Hing L Sham, Thomas Sowin, Saul H Rosenberg, Nan-Horng Lin.   

Abstract

The discovery of 1-(5-chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas as a new class of potent (IC(50) values of 3-10 nM) and selective inhibitors of Chk1 kinase was described. One of these compounds (2e) potentiates HeLa cells by over 22-fold against doxorubicin in an antiproliferation assay, and SW620 cells against camptothecin by 20-fold in an antiproliferation assay and 14-fold in a soft agar assay. Flow cytometry (FACS) analysis confirmed that 2e abrogated G2 checkpoint arrest of H1299 cells caused by doxorubicin and S checkpoint arrest caused by camptothecin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857116     DOI: 10.1021/jm048989d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

2.  3D-QSAR study of Chk1 kinase inhibitors based on docking.

Authors:  Lingzhou Zhao; Yongjuan Liu; Shiyuan Hu; Huabei Zhang
Journal:  J Mol Model       Date:  2012-02-25       Impact factor: 1.810

Review 3.  Targeting DNA repair and the cell cycle in glioblastoma.

Authors:  Brian M Alexander; Nancy Pinnell; Patrick Y Wen; Alan D'Andrea
Journal:  J Neurooncol       Date:  2011-11-24       Impact factor: 4.130

4.  CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

Authors:  Victoria E Anderson; Michael I Walton; Paul D Eve; Katherine J Boxall; Laurent Antoni; John J Caldwell; Wynne Aherne; Laurence H Pearl; Antony W Oliver; Ian Collins; Michelle D Garrett
Journal:  Cancer Res       Date:  2011-01-15       Impact factor: 12.701

Review 5.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

Review 6.  ATR/CHK1 inhibitors and cancer therapy.

Authors:  Zhaojun Qiu; Nancy L Oleinick; Junran Zhang
Journal:  Radiother Oncol       Date:  2017-10-18       Impact factor: 6.280

7.  Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors.

Authors:  Nour Jamal Jaradat; Mohammad A Khanfar; Maha Habash; Mutasem Omar Taha
Journal:  J Comput Aided Mol Des       Date:  2015-05-09       Impact factor: 3.686

8.  Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.

Authors:  Hiroyoshi Hattori; Ferdinandos Skoulidis; Paul Russell; Ashok R Venkitaraman
Journal:  Mol Cancer Ther       Date:  2011-02-02       Impact factor: 6.261

9.  Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.

Authors:  John C Reader; Thomas P Matthews; Suki Klair; Kwai-Ming J Cheung; Jane Scanlon; Nicolas Proisy; Glynn Addison; John Ellard; Nelly Piton; Suzanne Taylor; Michael Cherry; Martin Fisher; Kathy Boxall; Samantha Burns; Michael I Walton; Isaac M Westwood; Angela Hayes; Paul Eve; Melanie Valenti; Alexis de Haven Brandon; Gary Box; Rob L M van Montfort; David H Williams; G Wynne Aherne; Florence I Raynaud; Suzanne A Eccles; Michelle D Garrett; Ian Collins
Journal:  J Med Chem       Date:  2011-11-23       Impact factor: 7.446

Review 10.  Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Authors:  Gwenola Manic; Florine Obrist; Antonella Sistigu; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.